The DOI matches its Crossref record; 183 of the 183 references it cites were found in a registry or an index.
The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
Open accessAbstract
The recent success of PD-1 and PD-L1 blockade in cancer therapy illustrates the important role of the PD-1/PD-L1 pathway in the regulation of antitumor immune responses. However, signaling regulated by the PD-1/PD-L pathway is also associated with substantial inflammatory effects that can resemble those in autoimmune responses, chronic infection, and sepsis, consistent with the role of this pathway in balancing protective immunity and immunopathology, as well as in homeostasis and tolerance. Targeting PD-1/PD-L1 to treat cancer has shown benefits in many patients, suggesting a promising opportunity to target this pathway in autoimmune and inflammatory disorders. Here, we systematically evaluate the diverse biological functions of the PD-1/PD-L pathway in immune-mediated diseases and the relevant mechanisms that control these immune reactions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357 · cited 2×
“Unlike the majority of irAEs, endocrinopathies are usually irreversible (165).”
BackgroundFreeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Chen, G., Huang, A. C., Zhang, W., Zhang, G., Wu, M., Xu, W., Yu, Z., Yang, J., Wang, B., Sun, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0392-8 · Cited by 2,813
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308
The PD‐1 pathway in tolerance and autoimmunity
Francisco, L. M., Sage, P. T., & Sharpe, A. H. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00923.x · Cited by 2,300
Regulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,193
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
Im, S. J., Hashimoto, M., Gerner, M. Y., Lee, J., Kissick, H. T., Burger, M. C., Shan, Q., Hale, J. S., Lee, J., Nasti, T. H., et al. (2016) · Nature · doi:10.1038/nature19330 · Cited by 2,070
The diverse functions of the PD1 inhibitory pathway
Sharpe, A. H., & Pauken, K. E. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.108 · Cited by 1,971
Immunosuppression in Patients Who Die of Sepsis and Multiple Organ Failure
Boomer, J. S., To, K., Chang, K. C., Takasu, O., Osborne, D. F., Walton, A. H., Bricker, T. L., Jarman, S. D., Kreisel, D., Krupnick, A. S., et al. (2011) · JAMA · doi:10.1001/jama.2011.1829 · Cited by 1,781
Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., & Freeman, G. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.016 · Cited by 1,732
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes
Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubat, T., Yagita, H., & Honjo, T. (1996) · International Immunology · doi:10.1093/intimm/8.5.765 · Cited by 1,589
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,470
Langer, C. J., Gadgeel, S. M., Borghaei, H., Papadimitrakopoulou, V. A., Patnaik, A., Powell, S. F., Gentzler, R. D., Martins, R. G., Stevenson, J. P., Jalal, S. I., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30498-3 · Cited by 1,404
Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade
Pauken, K. E., Sammons, M. A., Odorizzi, P. M., Manne, S., Godec, J., Khan, O., Drake, A. M., Chen, Z., Sen, D. R., Kurachi, M., et al. (2016) · Science · doi:10.1126/science.aaf2807 · Cited by 1,348 · cited 1×
“Intriguingly, in some cases, PD-1 blockade first restored virus-specific CD8 T-cell function, but CD8 T cells subsequently became exhausted again, displaying resistance to PD-1 immunotherapy (129).”
BackgroundSchachter, J., Ribas, A., Long, G. V., Arance, A., Grob, J.-J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31601-x · Cited by 1,225
Tissue expression of PD-L1 mediates peripheral T cell tolerance
Keir, M. E., Liang, S. C., Guleria, I., Latchman, Y. E., Qipo, A., Albacker, L. A., Koulmanda, M., Freeman, G. J., Sayegh, M. H., & Sharpe, A. H. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051776 · Cited by 1,211
Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., & Saito, T. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112741 · Cited by 1,161 · cited 1×
“, ZAP70, PKCθ, and other kinases) (40).”
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
Kamada, T., Togashi, Y., Tay, C., Ha, D., Sasaki, A., Nakamura, Y., Sato, E., Fukuoka, S., Tada, Y., Tanaka, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1822001116 · Cited by 1,008
Expression of Programmed Death 1 Ligands by Murine T Cells and APC
Yamazaki, T., Akiba, H., Iwai, H., Matsuda, H., Aoki, M., Tanno, Y., Shin, T., Tsuchiya, H., Pardoll, D. M., Okumura, K., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.10.5538 · Cited by 951
Progenitor and Terminal Subsets of CD8 + T Cells Cooperate to Contain Chronic Viral Infection
Paley, M. A., Kroy, D. C., Odorizzi, P. M., Johnnidis, J. B., Dolfi, D. V., Barnett, B. E., Bikoff, E. K., Robertson, E. J., Lauer, G. M., Reiner, S. L., et al. (2012) · Science · doi:10.1126/science.1229620 · Cited by 902
TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection
Alfei, F., Kanev, K., Hofmann, M., Wu, M., Ghoneim, H. E., Roelli, P., Utzschneider, D. T., von Hoesslin, M., Cullen, J. G., Fan, Y., et al. (2019) · Nature · doi:10.1038/s41586-019-1326-9 · Cited by 899
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
(2015) · New England Journal of Medicine · doi:10.1056/nejmc1509660 · Cited by 872
Management of toxicities of immune checkpoint inhibitors
Spain, L., Diem, S., & Larkin, J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.001 · Cited by 854
Okazaki, T., Maeda, A., Nishimura, H., Kurosaki, T., & Honjo, T. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231486598 · Cited by 848
Seo, H., Chen, J., González-Avalos, E., Samaniego-Castruita, D., Das, A., Wang, Y. H., López-Moyado, I. F., Georges, R. O., Zhang, W., Onodera, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1905675116 · Cited by 808
Enhancing SIV-specific immunity in vivo by PD-1 blockade
Velu, V., Titanji, K., Zhu, B., Husain, S., Pladevega, A., Lai, L., Vanderford, T. H., Chennareddi, L., Silvestri, G., Freeman, G. J., et al. (2009) · Nature · doi:10.1038/nature07662 · Cited by 771
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
Mezzadra, R., Sun, C., Jae, L. T., Gomez-Eerland, R., de Vries, E., Wu, W., Logtenberg, M. E. W., Slagter, M., Rozeman, E. A., Hofland, I., et al. (2017) · Nature · doi:10.1038/nature23669 · Cited by 697
Follicular CXCR5-expressing CD8+ T cells curtail chronic viral infection
He, R., Hou, S., Liu, C., Zhang, A., Bai, Q., Han, M., Yang, Y., Wei, G., Shen, T., Yang, X., et al. (2016) · Nature · doi:10.1038/nature19317 · Cited by 677
Self-citationArlauckas, S. P., Garris, C. S., Kohler, R. H., Kitaoka, M., Cuccarese, M. F., Yang, K. S., Miller, M. A., Carlson, J. C., Freeman, G. J., Anthony, R. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3604 · Cited by 669
Osorio, J. C., Ni, A., Chaft, J. E., Pollina, R., Kasler, M. K., Stephens, D., Rodriguez, C., Cambridge, L., Rizvi, H., Wolchok, J. D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw640 · Cited by 659 · cited 1×
“In a report of thyroid disorders, these events occurred when patients with antithyroid antibodies received anti-PD-1 therapy, suggesting that anti-PD-1 treatment may regulate preexisting antithyroid antibodies (178).”
BackgroundAberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
Kataoka, K., Shiraishi, Y., Takeda, Y., Sakata, S., Matsumoto, M., Nagano, S., Maeda, T., Nagata, Y., Kitanaka, A., Mizuno, S., et al. (2016) · Nature · doi:10.1038/nature18294 · Cited by 651
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
Cortazar, F. B., Marrone, K. A., Troxell, M. L., Ralto, K. M., Hoenig, M. P., Brahmer, J. R., Le, D. T., Lipson, E. J., Glezerman, I. G., Wolchok, J., et al. (2016) · Kidney International · doi:10.1016/j.kint.2016.04.008 · Cited by 650
Sepsis-induced immune dysfunction: can immune therapies reduce mortality?
Delano, M. J., & Ward, P. A. (2016) · Journal of Clinical Investigation · doi:10.1172/jci82224 · Cited by 644
Latchman, Y. E., Liang, S. C., Wu, Y., Chernova, T., Sobel, R. A., Klemm, M., Kuchroo, V. K., Freeman, G. J., & Sharpe, A. H. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307252101 · Cited by 636
Selective expansion of a subset of exhausted CD8 T cells by αPD-L1 blockade
Blackburn, S. D., Shin, H., Freeman, G. J., & Wherry, E. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801497105 · Cited by 579
Immune checkpoint blockade in infectious diseases
Wykes, M. N., & Lewin, S. R. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.112 · Cited by 570
B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells
Azuma, T., Yao, S., Zhu, G., Flies, A. S., Flies, S. J., & Chen, L. (2008) · Blood · doi:10.1182/blood-2007-11-123141 · Cited by 531
Huang, X., Venet, F., Wang, Y. L., Lepape, A., Yuan, Z., Chen, Y., Swan, R., Kherouf, H., Monneret, G., Chung, C.-S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809422106 · Cited by 515
Immune Modulation in Cancer with Antibodies
Page, D. B., Postow, M. A., Callahan, M. K., Allison, J. P., & Wolchok, J. D. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-092012-112807 · Cited by 515
Kinter, A. L., Godbout, E. J., McNally, J. P., Sereti, I., Roby, G. A., O’Shea, M. A., & Fauci, A. S. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.6738 · Cited by 513
PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy
Dermani, F. K., Samadi, P., Rahmani, G., Kohlan, A. K., & Najafi, R. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27172 · Cited by 504
Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection
Butler, N. S., Moebius, J., Pewe, L. L., Traore, B., Doumbo, O. K., Tygrett, L. T., Waldschmidt, T. J., Crompton, P. D., & Harty, J. T. (2012) · Nature Immunology · doi:10.1038/ni.2180 · Cited by 482
Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells
Odorizzi, P. M., Pauken, K. E., Paley, M. A., Sharpe, A., & Wherry, E. J. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20142237 · Cited by 467
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade
Chen, L., Diao, L., Yang, Y., Yi, X., Rodriguez, B. L., Li, Y., Villalobos, P. A., Cascone, T., Liu, X., Tan, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1033 · Cited by 462 · cited 1×
“(181) found that tumor cells expressing CD38, which regulates the adenosine production pathway, escape from checkpoint inhibitor-mediated immune attack.”
BackgroundThe PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
Lin, D. Y.-W., Tanaka, Y., Iwasaki, M., Gittis, A. G., Su, H.-P., Mikami, B., Okazaki, T., Honjo, T., Minato, N., & Garboczi, D. N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712278105 · Cited by 457
PD-1 Controls Follicular T Helper Cell Positioning and Function
Shi, J., Hou, S., Fang, Q., Liu, X., Liu, X., & Qi, H. (2018) · Immunity · doi:10.1016/j.immuni.2018.06.012 · Cited by 449
Youngblood, B., Oestreich, K. J., Ha, S.-J., Duraiswamy, J., Akondy, R. S., West, E. E., Wei, Z., Lu, P., Austin, J. W., Riley, J. L., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.06.015 · Cited by 419
Lee, H.-H., Wang, Y.-N., Xia, W., Chen, C.-H., Rau, K.-M., Ye, L., Wei, Y., Chou, C.-K., Wang, S.-C., Yan, M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.06.008 · Cited by 405
Phospholipase Cγ activates Ras on the Golgi apparatus by means of RasGRP1
Bivona, T. G., Pérez de Castro, I., Ahearn, I. M., Grana, T. M., Chiu, V. K., Lockyer, P. J., Cullen, P. J., Pellicer, A., Cox, A. D., & Philips, M. R. (2003) · Nature · doi:10.1038/nature01806 · Cited by 402
He, J., Hu, Y., Hu, M., & Li, B. (2015) · Scientific Reports · doi:10.1038/srep13110 · Cited by 401
Staron, M. M., Gray, S. M., Marshall, H. D., Parish, I. A., Chen, J. H., Perry, C. J., Cui, G., Li, M. O., & Kaech, S. M. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.013 · Cited by 385
The PD-1/PD-Ls pathway and autoimmune diseases
Dai, S., Jia, R., Zhang, X., Fang, Q., & Huang, L. (2014) · Cellular Immunology · doi:10.1016/j.cellimm.2014.05.006 · Cited by 354
Self-citationGane, E., Verdon, D. J., Brooks, A. E., Gaggar, A., Nguyen, A. H., Subramanian, G. M., Schwabe, C., & Dunbar, P. R. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.028 · Cited by 345
Terawaki, S., Chikuma, S., Shibayama, S., Hayashi, T., Yoshida, T., Okazaki, T., & Honjo, T. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003208 · Cited by 342
CD4 T Cells Promote Rather than Control Tuberculosis in the Absence of PD-1–Mediated Inhibition
Barber, D. L., Mayer-Barber, K. D., Feng, C. G., Sharpe, A. H., & Sher, A. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003304 · Cited by 329
The changing immune system in sepsis: Is individualized immuno-modulatory therapy the answer?
Boomer, J. S., Green, J. M., & Hotchkiss, R. S. (2014) · Virulence · doi:10.4161/viru.26516 · Cited by 317
Kythreotou, A., Siddique, A., Mauri, F. A., Bower, M., & Pinato, D. J. (2018) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2017-204853 · Cited by 317
Zhang, Y., Zhou, Y., Lou, J., Li, J., Bo, L., Zhu, K., Wan, X., Deng, X., & Cai, Z. (2010) · Critical Care · doi:10.1186/cc9354 · Cited by 308
Self-citationSingle-cell RNA-seq identifies a PD-1hi ILC progenitor and defines its development pathway
Yu, Y., Tsang, J. C. H., Wang, C., Clare, S., Wang, J., Chen, X., Brandt, C., Kane, L., Campos, L. S., Lu, L., et al. (2016) · Nature · doi:10.1038/nature20105 · Cited by 306
Role of PD-1 in Regulating T-Cell Immunity
Jin, H.-T., Ahmed, R., & Okazaki, T. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2010_116 · Cited by 305
Brahmamdam, P., Inoue, S., Unsinger, J., Chang, K. C., McDunn, J. E., & Hotchkiss, R. S. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0110037 · Cited by 305
Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape
Noguchi, T., Ward, J. P., Gubin, M. M., Arthur, C. D., Lee, S. H., Hundal, J., Selby, M. J., Graziano, R. F., Mardis, E. R., Korman, A. J., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0391 · Cited by 302
Wang, S., Bajorath, J., Flies, D. B., Dong, H., Honjo, T., & Chen, L. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021752 · Cited by 291
Chang, K. C., Burnham, C.-A., Compton, S. M., Rasche, D. P., Mazuski, R., SMcDonough, J., Unsinger, J., Korman, A. J., Green, J. M., & Hotchkiss, R. S. (2013) · Critical Care · doi:10.1186/cc12711 · Cited by 281
Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity
Gianchecchi, E., Delfino, D. V., & Fierabracci, A. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.05.003 · Cited by 270
Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies
Sibaud, V., Meyer, N., Lamant, L., Vigarios, E., Mazieres, J., & Delord, J. P. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000290 · Cited by 265
Fujita, Y., Yagishita, S., Hagiwara, K., Yoshioka, Y., Kosaka, N., Takeshita, F., Fujiwara, T., Tsuta, K., Nokihara, H., Tamura, T., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.10 · Cited by 261
Defining and analyzing geoepidemiology and human autoimmunity
Shapira, Y., Agmon-Levin, N., & Shoenfeld, Y. (2010) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.11.018 · Cited by 260
PD-1 Regulates Self-Reactive CD8+ T Cell Responses to Antigen in Lymph Nodes and Tissues
Keir, M. E., Freeman, G. J., & Sharpe, A. H. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.8.5064 · Cited by 245
Polanczyk, M. J., Hopke, C., Vandenbark, A. A., & Offner, H. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.20881 · Cited by 244
Chen, Y., Wang, Q., Shi, B., Xu, P., Hu, Z., Bai, L., & Zhang, X. (2011) · Cytokine · doi:10.1016/j.cyto.2011.06.004 · Cited by 243
Self-citationTeng, F., Meng, X., Kong, L., & Yu, J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.11.014 · Cited by 243
PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1
Chen, G., Kim, Y. H., Li, H., Luo, H., Liu, D.-L., Zhang, Z.-J., Lay, M., Chang, W., Zhang, Y.-Q., & Ji, R.-R. (2017) · Nature Neuroscience · doi:10.1038/nn.4571 · Cited by 240
Self-citationGardiner, D., Lalezari, J., Lawitz, E., DiMicco, M., Ghalib, R., Reddy, K. R., Chang, K.-M., Sulkowski, M., Marro, S. O., Anderson, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063818 · Cited by 231
Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade
Zhang, F., Wei, H., Wang, X., Bai, Y., Wang, P., Wu, J., Jiang, X., Wang, Y., Cai, H., Xu, T., et al. (2017) · Cell Discovery · doi:10.1038/celldisc.2017.4 · Cited by 226
Self-citationGay, C. L., Bosch, R. J., Ritz, J., Hataye, J. M., Aga, E., Tressler, R. L., Mason, S. W., Hwang, C. K., Grasela, D. M., Ray, N., et al. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix191 · Cited by 224
Cutaneous adverse effects of the immune checkpoint inhibitors
Collins, L. K., Chapman, M. S., Carter, J. B., & Samie, F. H. (2017) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2016.12.001 · Cited by 219
Patera, A. C., Drewry, A. M., Chang, K., Beiter, E. R., Osborne, D., & Hotchkiss, R. S. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.4hi0616-255r · Cited by 217
Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice
Frebel, H., Nindl, V., Schuepbach, R. A., Braunschweiler, T., Richter, K., Vogel, J., Wagner, C. A., Loffing-Cueni, D., Kurrer, M., Ludewig, B., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20121015 · Cited by 209
Li, J., Lee, Y., Li, Y., Jiang, Y., Lu, H., Zang, W., Zhao, X., Liu, L., Chen, Y., Tan, H., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.018 · Cited by 209
Self-citationPD-1 on dendritic cells impedes innate immunity against bacterial infection
Yao, S., Wang, S., Zhu, Y., Luo, L., Zhu, G., Flies, S., Xu, H., Ruff, W., Broadwater, M., Choi, I.-H., et al. (2009) · Blood · doi:10.1182/blood-2009-02-203141 · Cited by 208
Role of PD-1 in Immunity and Diseases
Chamoto, K., Al-Habsi, M., & Honjo, T. (2017) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2017_67 · Cited by 200
Nishimura, H., Honjo, T., & Minato, N. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.5.891 · Cited by 192
The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis
Suresh, K., Naidoo, J., Zhong, Q., Xiong, Y., Mammen, J., de Flores, M. V., Cappelli, L., Balaji, A., Palmer, T., Forde, P. M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci128654 · Cited by 192
Raptopoulou, A. P., Bertsias, G., Makrygiannakis, D., Verginis, P., Kritikos, I., Tzardi, M., Klareskog, L., Catrina, A. I., Sidiropoulos, P., & Boumpas, D. T. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27500 · Cited by 191
Yang, J., & Hu, L. (2019) · Medicinal Research Reviews · doi:10.1002/med.21530 · Cited by 190
Self-citationNew immunotherapies targeting the PD-1 pathway
Chinai, J. M., Janakiram, M., Chen, F., Chen, W., Kaplan, M., & Zang, X. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.06.005 · Cited by 189
Patsoukis, N., Li, L., Sari, D., Petkova, V., & Boussiotis, V. A. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00319-13 · Cited by 187
Carter, L. L., Leach, M. W., Azoitei, M. L., Cui, J., Pelker, J. W., Jussif, J., Benoit, S., Ireland, G., Luxenberg, D., Askew, G. R., et al. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.10.006 · Cited by 183
Diversification of human plasmacytoid predendritic cells in response to a single stimulus
Alculumbre, S. G., Saint‐André, V., Domizio, J. D., Vargas, P., Sirven, P., Bost, P., Maurin, M., Maiuri, P., Wéry, M., Jouve, M. J., et al. (2017) · Nature Immunology · doi:10.1038/s41590-017-0012-z · Cited by 179
Bioactive Macrocyclic Inhibitors of the PD‐1/PD‐L1 Immune Checkpoint
Magiera‐Mularz, K., Skalniak, L., Zak, K. M., Musielak, B., Rudzinska‐Szostak, E., Berlicki, Ł., Kocik, J., Grudnik, P., Sala, D., Zarganes‐Tzitzikas, T., et al. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201707707 · Cited by 175
Fuller, M. J., Callendret, B., Zhu, B., Freeman, G. J., Hasselschwert, D. L., Satterfield, W., Sharpe, A. H., Dustin, L. B., Rice, C. M., Grakoui, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1312772110 · Cited by 173
Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection
Hoffmann, M., Pantazis, N., Martin, G. E., Hickling, S., Hurst, J. M., Meyerowitz, J., Willberg, C. B., Robinson, N., Brown, H. L., Fisher, M., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005661 · Cited by 173
Immune and molecular correlates in melanoma treated with immune checkpoint blockade
Byrne, E. H., & Fisher, D. E. (2017) · Cancer · doi:10.1002/cncr.30444 · Cited by 172
Zhu, J., Chen, L., Zou, L., Yang, P., Wu, R., Mao, Y., Zhou, H., Li, R., Wang, K., Wang, W., et al. (2014) · Human Immunology · doi:10.1016/j.humimm.2014.01.006 · Cited by 171
Self-citationGhebeh, H., Tulbah, A. M., Mohammed, S. F., Elkum, N. B., Amer, S. M. B., Al‐Tweigeri, T., & Dermime, S. (2007) · International Journal of Cancer · doi:10.1002/ijc.22703 · Cited by 171
Immunological biomarkers predict HIV-1 viral rebound after treatment interruption
Hurst, J., Hoffmann, M., Pace, M., Williams, J. P., Thornhill, J., Hamlyn, E., Meyerowitz, J., Willberg, C., Koelsch, K. K., Robinson, N., et al. (2015) · Nature Communications · doi:10.1038/ncomms9495 · Cited by 170
In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses
Shin, T., Yoshimura, K., Shin, T., Crafton, E. B., Tsuchiya, H., Housseau, F., Koseki, H., Schulick, R. D., Chen, L., & Pardoll, D. M. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050072 · Cited by 168
Liu, Y., Carlsson, R., Comabella, M., Wang, J., Kosicki, M., Carrión, B., Hasan, M., Wu, X., Montalbán, X., Dziegiel, M. H., et al. (2014) · Nature Medicine · doi:10.1038/nm.3485 · Cited by 167
MiR-873/PD-L1 axis regulates the stemness of breast cancer cells
Gao, L., Guo, Q., Li, X., Yang, X., Ni, H., Wang, T., Zhao, Q., Liu, H., Xing, Y., Xi, T., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.034 · Cited by 163
Targeting Immune Cell Checkpoints during Sepsis
Patil, N., Guo, Y., Luan, L., & Sherwood, E. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112413 · Cited by 162
Quatrini, L., Wieduwild, É., Escalière, B., Filtjens, J., Chasson, L., Laprie, C., Vivier, É., & Ugolini, S. (2018) · Nature Immunology · doi:10.1038/s41590-018-0185-0 · Cited by 162
Shao, R., Fang, Y., Han, Y., Zhao, L., Jiang, Z., & Li, C. (2016) · Critical Care · doi:10.1186/s13054-016-1301-x · Cited by 161
Liver-Resident NK Cells Control Antiviral Activity of Hepatic T Cells via the PD-1-PD-L1 Axis
Zhou, J., Peng, H., Li, K., Qu, K., Wang, B., Wu, Y., Ye, L., Dong, Z., Wei, H., Sun, R., et al. (2019) · Immunity · doi:10.1016/j.immuni.2018.12.024 · Cited by 157
Heinzerling, L., Toni, E. D., Schett, G. A., Hundorfean, G., & Zimmer, L. (2019) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2019.0119 · Cited by 156
Dong, Y., Li, X., Zhang, L., Zhu, Q., Chen, C., Bao, J., & Chen, Y. (2019) · BMC Immunology · doi:10.1186/s12865-019-0309-9 · Cited by 155
Li, P., Mao, L., Liu, X., Gan, Y., Zheng, J., Thomson, A. W., Gao, Y., Chen, J., & Hu, X. (2014) · Stroke · doi:10.1161/strokeaha.113.004100 · Cited by 144
Rutigliano, J. A., Sharma, S., Morris, M. Y., Oguin, T. H., McClaren, J. L., Doherty, P. C., & Thomas, P. G. (2013) · Journal of Virology · doi:10.1128/jvi.02851-13 · Cited by 138
Titanji, K., Velu, V., Chennareddi, L. S., Vijay–Kumar, M., Gewirtz, A. T., Freeman, G. J., & Amara, R. R. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43271 · Cited by 134
Kuol, N., Stojanovska, L., Nurgali, K., & Apostolopoulos, V. (2017) · Immunotherapy · doi:10.2217/imt-2017-0120 · Cited by 132
Hafalla, J. C. R., Claser, C., Couper, K. N., Grau, G. E., Rénia, L., de Souza, J. B., & Riley, E. M. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002504 · Cited by 131
Blank, C. U., Brown, I., Marks, R., Nishimura, H., Honjo, T., & Gajewski, T. F. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.9.4574 · Cited by 131
Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm
Rao, M., Valentini, D., Dodoo, E., Zumla, A. I., & Maeurer, M. J. (2017) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2017.01.028 · Cited by 131
Guan, J., Lim, K. S., Mekhail, T. M., & Chang, C.-C. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0361-ra · Cited by 131
TGFβ-dependent expression of PD-1 and PD-L1 controls CD8+ T cell anergy in transplant tolerance
Baas, M. C., Besançon, A., Goncalves, T., Valette, F., Yagita∥, H., Sawitzki, B., Volk, H., Waeckel-Énée, E., Rocha, B., Chatenoud, L., et al. (2016) · eLife · doi:10.7554/elife.08133 · Cited by 125
Wang, J., Li, J., Zhao, Y.-J., Yi, W., Bian, J., Wan, X., Zhu, K., & Deng, X. (2014) · Anesthesiology · doi:10.1097/aln.0000000000000525 · Cited by 124
Self-citationBertsias, G. K., Nakou, M., Choulaki, C., Raptopoulou, A., Papadimitraki, E. D., Goulielmos, G. N., Kritikos, H. D., Sidiropoulos, P. I., Tzardi, M. N., Kardassis, D., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.24227 · Cited by 122
Ashizawa, M., Okayama, H., Ishigame, T., Min, A. K. T., Saito, K., Ujiie, D., Murakami, Y., Kikuchi, T., Nakayama, Y., Noda, M., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0831 · Cited by 121
Koronyo‐Hamaoui, M., Ko, M. K., Koronyo, Y., Azoulay, D., Seksenyan, A., Kunis, G., Pham, M. D., Bakhsheshian, J., Rogeri, P. S., Black, K. L., et al. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06402.x · Cited by 120
Metabolic exhaustion in infection, cancer and autoimmunity
McKinney, E. F., & Smith, K. G. C. (2018) · Nature Immunology · doi:10.1038/s41590-018-0045-y · Cited by 119
Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?
van der Vlist, M., Kuball, J. H. E., Radstake, T. R. D. J., & Meyaard, L. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.131 · Cited by 118
Combinatorial Cancer Immunotherapies
Hellmann, M. D., Friedman, C. F., & Wolchok, J. D. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.005 · Cited by 117
Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways
Liu, C., Jiang, J., Gao, L., Wang, X., Hu, X., Wu, M., Wu, J. H., Xu, T., Shi, Q., & Zhang, X. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0859-z · Cited by 116
Self-citationFujisawa, R., Haseda, F., Tsutsumi, C., Hiromine, Y., Noso, S., Kawabata, Y., Mitsui, S., Terasaki, J., Ikegami, H., Imagawa, A., et al. (2015) · Clinical & Experimental Immunology · doi:10.1111/cei.12603 · Cited by 115
Toxicities Associated With PD-1/PD-L1 Blockade
Wang, D. Y., Johnson, D. B., & Davis, E. J. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000296 · Cited by 114
Karunarathne, D. S., Horne‐Debets, J. M., Huang, J. X., Faleiro, R. J., Leow, C. Y., Amante, F. H., Watkins, T. S., Miles, J. J., Dwyer, P., Stacey, K. J., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.017 · Cited by 106
Protective effects of Fc-fused PD-L1 on two different animal models of colitis
Song, M.-Y., Hong, C., Park, S. J., Kim, J.-H., Yang, B., Park, Y., Kim, S. W., Kim, K. S., Lee, J. Y., Lee, S., et al. (2014) · Gut · doi:10.1136/gutjnl-2014-307311 · Cited by 105
Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant
Pascolutti, R., Sun, X., Kao, J., Maute, R. L., Ring, A. M., Bowman, G. R., & Kruse, A. C. (2016) · Structure · doi:10.1016/j.str.2016.06.026 · Cited by 102
Yu, J., Yan, J., Guo, Q., Chi, Z., Tang, B., Zheng, B., Yu, J., Yin, T., Cheng, Z., Wu, X., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0475 · Cited by 100
Self-citationTrabattoni, D., Saresella, M., Pacei, M., Marventano, I., Mendozzi, L., Rovaris, M., Caputo, D., Borelli, M., & Clerici, M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901038 · Cited by 99
Pauken, K. E., Jenkins, M. K., Azuma, M., & Fife, B. T. (2013) · Diabetes · doi:10.2337/db12-1475 · Cited by 95
Both PD-1 Ligands Protect the Kidney from Ischemia Reperfusion Injury
Jaworska, K., Ratajczak, J., Huang, L., Whalen, K., Yang, M., Stevens, B. K., & Kinsey, G. R. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400497 · Cited by 93
Tousif, S., Singh, Y., Prasad, D. V. R., Sharma, P., Kaer, L. V., & Das, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019864 · Cited by 93
Álvarez‐Sierra, D., Marín, A., Ruiz-Blázquez, P., de Jesús‐Gil, C., Iglesias, C., González, Ó., Casteràs, A., Ferrer, R., Nuciforo, P. G., Colobrán, R., et al. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.05.013 · Cited by 93
Affinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor
Peled, M., Tocheva, A. S., Sandigursky, S., Nayak, S., Philips, E. A., Nichols, K. E., Strazza, M., Azoulay-Alfaguter, I., Askenazi, M., Neel, B. G., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710437115 · Cited by 87
Fierabracci, A., Milillo, A., Locatelli, F., & Fruci, D. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.04.007 · Cited by 87
Huang, X., Chen, Y., Chung, C., Yuan, Z., Monaghan, S. F., Wang, F., & Ayala, A. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1302252 · Cited by 84
Ren, X. S., Akiyoshi, K., Vandenbark, A. A., Hurn, P. D., & Offner, H. (2011) · Stroke · doi:10.1161/strokeaha.111.613182 · Cited by 84
Kim, J. H., Choi, Y. J., Lee, B. H., Song, M.-Y., Ban, C. Y., Kim, J., Park, J., Kim, S., Kim, T.-G., Park, S., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.11.021 · Cited by 82
Jacobi, F., Wild, K., Smits, M., Zoldan, K., Csernalabics, B., Flecken, T., Lang‐Meli, J., Ehrenmann, P., Emmerich, F., Hofmann, M., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.016 · Cited by 79
TNF-α and TGF-β Counter-Regulate PD-L1 Expression on Monocytes in Systemic Lupus Erythematosus
Ou, J.-N., WIEDEMAN, A. E., & Stevens, A. M. (2012) · Scientific Reports · doi:10.1038/srep00295 · Cited by 77
Bodhankar, S., Chen, Y., Vandenbark, A. A., Murphy, S. J., & Offner, H. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-111 · Cited by 74
Kim, J.-Y., Park, M., Kim, Y., Ryu, K., Lee, K. H., Cho, K., & Woo, S. (2017) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.2423 · Cited by 74
Immune checkpoint receptors: homeostatic regulators of immunity
Riva, A., & Chokshi, S. (2018) · Hepatology International · doi:10.1007/s12072-018-9867-9 · Cited by 74
Wong, M., Cava, A. L., & Hahn, B. H. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202382 · Cited by 73
Luo, Q., Huang, Z., Ye, J., Deng, Y., Fang, L., Li, X., Guo, Y., Jiang, H., Ju, B., Huang, Q., et al. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-0942-0 · Cited by 73
Self-citationPD-1 checkpoint inhibition: Toxicities and management
Hahn, A. W., Gill, D. M., Agarwal, N., & Maughan, B. L. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.08.005 · Cited by 73
Ji, H., Shen, X., GAO, F. G., Ke, B., Freitas, M. C. S., Uchida, Y., Busuttil, R. W., Zhai, Y., & Kupiec‐Weglinski, J. W. (2010) · Hepatology · doi:10.1002/hep.23843 · Cited by 70
Tissue-Expressed B7-H1 Critically Controls Intestinal Inflammation
Scandiuzzi, L., Ghosh, K., Hofmeyer, K. A., Abadi, Y. M., Lázár‐Molnár, E., Lin, E. Y., Liu, Q., Jeon, H., Almo, S. C., Chen, L., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.01.020 · Cited by 68
Are autoimmune diseases predictable?
Tobón, G. J., Pers, J., Cañas, C. A., Rojas‐Villarraga, A., Youinou, P., & Anaya, J. (2011) · Autoimmunity Reviews · doi:10.1016/j.autrev.2011.10.004 · Cited by 68
Role of T‐Cell Dysfunction, Inflammation, and Coagulation in Microvascular Disease in HIV
Sinha, A., Ma, Y., Scherzer, R., Hur, S., Li, D., Ganz, P., Deeks, S. G., & Hsue, P. Y. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.004243 · Cited by 68
Shive, C. L., Clagett, B. M., McCausland, M. R., Mudd, J. C., Funderburg, N., Freeman, M. L., Younes, S., Ferrari, B., Rodriguez, B. A., McComsey, G. A., et al. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000913 · Cited by 66
A potential role for the PD1/PD-L1 pathway in the neuroinflammation of Alzheimer's disease
Saresella, M., Calabrese, E., Marventano, I., Piancone, F., Gatti, A. V., Farina, E., Alberoni, M., & Clerici, M. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.03.004 · Cited by 59
Sepsis Induces a Dysregulated Neutrophil Phenotype That Is Associated with Increased Mortality
Patel, J., Sapey, E., Parekh, D., Scott, A., Dosanjh, D. P. S., Gao, F., & THICKETT, D. R. (2018) · Mediators of Inflammation · doi:10.1155/2018/4065362 · Cited by 57
PD-L1 Blockade Attenuated Sepsis-Induced Liver Injury in a Mouse Cecal Ligation and Puncture Model
Zhu, W., Bao, R., Fan, X., Tao, T., Zhu, J., Wang, J., Li, J., Bo, L., & Deng, X. (2013) · Mediators of Inflammation · doi:10.1155/2013/361501 · Cited by 56
Self-citationSuarez, G. V., Ganzarain, C. M., Vecchione, M. B., Trifone, C., Franco, J. L. M., Genoula, M., Moraña, E. J., Balboa, L., & Quiroga, M. F. (2019) · Scientific Reports · doi:10.1038/s41598-018-36403-2 · Cited by 56
Zhao, S., Li, F., Leak, R. K., Chen, J., & Hu, X. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00271 · Cited by 55
Pizarro, C., García‐Díaz, D. F., Ethel Codner, D., Salas‐Pérez, F., Carrasco, E., & Pérez‐Bravo, F. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2552 · Cited by 51
Tang, L., Bai, J., Chung, C., Lomas‐Neira, J., Chen, Y., Huang, X., & Ayala, A. (2014) · Journal of Leukocyte Biology · doi:10.1189/jlb.4ma1213-647rr · Cited by 46
Association of PD-1 and PD-L1 Genetic Polymorphyisms with Type 1 Diabetes Susceptibility
Qian, C., Guo, H., Chen, X., Shi, A., Li, S., Wang, X., Pan, J., & Fang, C. (2018) · Journal of Diabetes Research · doi:10.1155/2018/1614683 · Cited by 43
Self-citationKim, Y. S., Park, G. B., Lee, H.-K., Song, H., Choi, I., Lee, W. J., & Hur, D. Y. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.9.6158 · Cited by 40
Yan, K., Sun, D., Jiang, G., Kaplan, H. J., & Shao, H. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0610332 · Cited by 39
Programmed Cell Death-1 Receptor (PD-1)-Mediated Regulation of Innate Lymphoid Cells
Mallett, G., Laurence, A. D. J., & Amarnath, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112836 · Cited by 32
Xiong, H.-Y., Ma, T., Wu, B., Lin, Y., & Tu, Z. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.14.5767 · Cited by 31
Xu, D., Fu, H.-H., Obar, J., Park, J.-J., Tamada, K., Yagita, H., & Lefrançois, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056539 · Cited by 28
Cancer therapies in HIV cure research
Rasmussen, T. A., Anderson, J. L., Wightman, F., & Lewin, S. R. (2016) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000328 · Cited by 23
Lack of PD-L1 Expression by iNKT Cells Improves the Course of Influenza A Infection
Maazi, H., Singh, A. K., Speak, A. O., Lombardi, V., Lam, J., Khoo, B., Inn, K. S., Sharpe, A. H., Jung, J. U., & Akbari, O. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059599 · Cited by 22
Dysregulation of the PD-1/PD-L1 pathway contributes to the pathogenesis of celiac disease
de León, C. P., López‐Casado, M. Á., Lorite, P., Palomeque, T., & Torres, M. I. (2019) · Cellular and Molecular Immunology · doi:10.1038/s41423-019-0256-7 · Cited by 14
Cited by
Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies
Tang, Y., Liu, J., Zhang, D., Xu, Z., Ji, J., & Wen, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01708 · Cited by 1,094
“, sepsis), as this pathway plays a role in balancing protective immunity and immunopathology (72).”
BackgroundWu, M., Huang, Q., Xie, Y., Wu, X., Ma, H., Zhang, Y., & Xia, Y. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01242-2 · Cited by 456
Regulation of PD-L1 Expression by NF-κB in Cancer
Antonangeli, F., Natalini, A., Garassino, M. C., Sica, A., Santoni, A., & Di Rosa, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.584626 · Cited by 385
Signal pathways of melanoma and targeted therapy
Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 379
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C.-H., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 363
Metadata
- Authors
- Qin, W., Hu, L., Zhang, X., Jiang, S., Li, J., Zhang, Z., & Wang, X.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2019-10-04
- Volume
- 10
- Pages
- 2298-2298
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2977648831
- Cited by
- 369
- References
- 183
- FWCI
- 16.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.